Test Price
2,800 AED✅ Home Collection Available
NALCN Gene – Neuroaxonal Neurodegeneration, Infantile, with Facial Dysmorphism – Genetic Test in UAE | 2800 AED | DHA Licensed & Compliant
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation with a specialized genetic counselor.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (all major UAE insurers accepted).
Test Overview & Methodology
This Next-Generation Sequencing (NGS) test fully analyzes the NALCN gene to detect pathogenic variants causing infantile neuroaxonal neurodegeneration with facial dysmorphism—a severe early-onset neurological disorder. In the UAE, our ISO‑certified genomic laboratory delivers the definitive diagnosis with turnaround in 3–4 weeks, empowering families and clinicians with critical data for precision management and genetic counseling.
| Feature | Our Test (DHA Approved) | Closest Alternative |
|---|---|---|
| Precision | Full gene coverage via NGS with >99.9% analytical sensitivity and specificity | Targeted mutation panels – miss rare/novel variants |
| Method | NGS (Next Generation Sequencing) with copy-number analysis | Sanger sequencing (single-exon focus) – lower resolution |
| Turnaround | 3–4 weeks from accession | 6–10 weeks (overseas send-out) |
Physician Insight & Safety Protocols
“This NALCN genetic test provides critical information, but it must be interpreted within the complete clinical picture. A negative result does not fully exclude the condition, and a positive result requires immediate multidisciplinary follow-up. Pre- and post-test genetic counseling is essential for informed decision-making.”
Medication Safety Advisory
Do not discontinue any prescribed medication or adjust treatment based solely on this test result without direct consultation with your managing physician. Sudden discontinuation of anticonvulsants, neuroprotective agents, or supplements can be life‑threatening.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inadequate sample (less than 1 µg of genomic DNA or incorrectly stored specimen) will require recollection.
- Exclusion: Patients who have received an allogeneic bone marrow transplant within the past 90 days – donor DNA may confound results.
- Emergency Red Flag – Seek immediate medical attention if: The child develops uncontrolled seizures, acute respiratory distress, or signs of acute metabolic decompensation (vomiting, lethargy, hypoglycemia) unrelated to the testing process.
Patient FAQ & Clinical Guidance
1. What does a positive NALCN gene mutation mean for my child’s future?
A positive result confirms a genetic diagnosis of infantile neuroaxonal neurodegeneration with facial dysmorphism, providing prognostic clarity and guiding early interventions such as antiepileptic management and nutritional support. Your genetic counselor will explain the inheritance pattern (autosomal dominant/de novo), recurrence risk for future pregnancies, and connect you with a pediatric neurology multidisciplinary team in the UAE.
2. How is the test performed and is it painful for my infant?
A simple venipuncture (1–2 ml of whole blood) or a painless finger‑prick onto an FTA card is sufficient; our pediatric‑trained phlebotomists use numbing creams and distraction techniques to ensure minimal discomfort. Home collection makes it even less stressful. The sample is then shipped under strict cold‑chain conditions to our ISO‑certified genomics laboratory for NGS analysis.
3. Can I use this result for insurance and disability claims in the UAE?
Our DHA‑compliant report includes all necessary ICD‑10 and LOINC codes and is accepted by all major UAE insurers and government disability authorities, provided you present the original certified report issued by our medical director. We assist with direct billing verification and supply any additional documentation required for Emirates ID‑linked medical records under UAE PDPL data‑protection standards.
UAE Regulatory & Data Privacy Adherence
This test is performed under DHA Facility License Number 1143. The laboratory adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, access-controlled, and processed solely for diagnostic purposes. Your privacy rights under UAE law are fully respected.
Accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). All genetic counseling and consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure patient safety and informed consent.
Clinical & Logistical Metadata
| Test Name | NALCN Gene – Neuroaxonal Neurodegeneration, Infantile, with Facial Dysmorphism – Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample accession |
| Sample Type / Matrix | Peripheral whole blood (1–2 ml) or FTA card finger-prick |
| Methodology Used | Next-Generation Sequencing (NGS) with copy-number analysis |
| ICD-10-CM Code | G31.89 (Other specified degenerative diseases of nervous system) |
| LOINC Code | 21637-3 (Gene analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians